Latest Biopharmaceutical News

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.

Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

Radiopharm Theranostics has reached the halfway mark in enrolling patients for its Phase 2b trial of RAD101, a novel imaging agent targeting brain metastases. Early data suggest RAD101 may outperform MRI in distinguishing tumor recurrence from radiation damage.

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

Immuron Limited reports progress on its IMM-529 FDA application and a delay in Travelan® clinical trial results due to a U.S. government shutdown, with key data now expected in late November.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.